Monoclonal antibody against pseudorabies virus gE protein and its application
By preparing monoclonal antibodies against porcine pseudorabies virus gE protein and combining enzyme-linked immunosorbent assays, the problem of insufficient sensitivity and specificity of existing detection methods is solved, and a rapid, sensitive and highly specific pig pseudorabies virus is achieved. Testing, suitable for large-scale clinical applications.
Patent Information
- Application Number
- CN202211552455.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-05
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2042-12-05
AI Technical Summary
The existing porcine pseudorabies virus gE protein detection methods have insufficient sensitivity and specificity, and are inconvenient to large-scale clinical testing. The existing diagnostic reagents have false positives and complex operation problems, making it difficult to meet fast, sensitive and highly specific detection. need.
Monoclonal antibodies against porcine pseudorabies virus gE protein were prepared, recombinant proteins were prepared through insect cell expression, and combined with enzyme-linked immunosorbent assays, and highly specific and highly sensitive detection reagents were developed.
It realizes rapid, sensitive and highly specific detection of porcine pseudorabies virus, reduces the false positive rate, is suitable for large-scale clinical applications, and is simple, economical and practical.
Smart Images

Figure CN115819563B_ABST
Abstract
Description
Technical Field
[0001] The embodiments of the present invention relate to the field of biotechnology, and in particular to a monoclonal antibody against porcine pseudorabies virus gE protein and an application thereof. Background Art
[0002] Pseudorabies virus (PR) belongs to the Herpesviridae family, the α-herpesvirinae subfamily, and the genus Varicella virus. It can cause testicular swelling or atrophy in boars, loss of fertility, miscarriage in pregnant sows, stillbirth, mummified fetuses, vomiting and diarrhea in young pigs, loss of appetite, and ultimately death from systemic failure. The virus can lurk in the host without causing disease and is easily mixed with other bacteria and viruses. Data show that although the feeding and management level of pig farms has improved in recent years and vaccines have been widely used, the prevalence of wild PRV in pig herds is still relatively serious, and PRV poses a huge threat to the pig farming industry. There are many vaccines for this virus disease: attenuated live vaccine, inactivated vaccine, gene-deficient vaccine, recombinant vector vaccine, subunit vaccine, nucleic acid vaccine, etc.
[0003] PRV is a double-stranded DNA virus that is round or oval in shape when observed under an electron microscope. It is composed of a capsid, a capsule and a nucleolus, and the particle diameter is between 150-180 nm. The genome is 143 Kb long and the GC content is as high as about 72%. Pseudorabies virus in pigs is mainly prevented by immunizing with a gE gene-deficient vaccine, and the gE antibody serological diagnosis method is used to distinguish between animals infected with wild strains and animals immunized with vaccines. Therefore, the diagnostic method of detecting protein antibodies can determine the resistance of animals to virus strains. At the same time, by monitoring the production of antibodies by vaccines, it can be an important means of daily monitoring of the group to select vaccines, evaluate the rationality of the immunization program, and grasp the health status. It can also be an important basis for determining the time point of vaccination.
[0004] At present, the diagnostic reagents for detecting the disease are uneven. In terms of both sensitivity and specificity, the isolation of PRV is considered the "gold standard" for identifying the virus. This method is only applicable to laboratory testing, and any error in the processing of samples, inoculation of cells, etc. will lead to failure of virus isolation, and it takes a long time to detect. The serum neutralization test has a fast reaction and strong specificity, but low sensitivity. The test results will be affected by different virus titers. At the same time, it has high requirements for samples and is not suitable for large-scale clinical testing.
[0005] The enzyme-linked immunosorbent assay (ELISA) has the advantages of being fast, simple, cheap, and capable of automatic batch testing, but it has the disadvantages of low specificity, high sensitivity, and prone to false positives. It requires an ELISA reader for determination, and is not suitable for testing a single sample. Immunofluorescence staining technology has the advantages of being simple, convenient, accurate, and rapid, and is often used for the diagnosis of pseudorabies virus. However, this method also has the disadvantage of cross-specificity and is not suitable for large-scale testing. The latex agglutination test is similar to the ELISA test and is often used for early infection detection. It has high sensitivity and specificity, and can be used for rapid serum screening tests. The agar immunodiffusion test is simple to operate, cost-effective, and has a wider range of applications, but the sensitivity of the test is affected by the method of extracting the antigen and the reliability of the positive serum, which brings inconvenience to the test.
[0006] The polymerase chain reaction is suitable for the amplification of PRV DNA and the clinical detection of PRV latent infection. At the same time, it can quickly differentiate the vaccine virus and wild virus of pseudorabies. However, the detection requires a dedicated detection instrument, which is expensive and has high requirements for the detection environment, so it is not very suitable for grassroots detection.
[0007] In summary, the above detection methods are widely used in the clinical detection of pseudorabies virus gE gene in pigs, but there are still various defects and they need to be further improved. Therefore, how to prepare specific antibodies for pseudorabies virus gE protein in pigs and establish a rapid, sensitive, highly specific, simple to operate, economical and practical diagnostic reagent and diagnostic method is of great significance for the clinical accurate detection of pseudorabies virus in pigs. Summary of the invention
[0008] To this end, the embodiments of the present invention provide monoclonal antibodies against porcine pseudorabies virus gE protein and applications thereof.
[0009] In order to achieve the above purpose, the embodiment of the present invention provides the following technical solutions:
[0010] The present invention provides a monoclonal antibody or a functional fragment thereof against the gE protein of pseudorabies virus.
[0011] The monoclonal antibody contains a H The heavy chain variable region and the name V L The light chain variable region of
[0012] The V H and V L Both consist of complementarity determining regions and framework regions;
[0013] The complementary determining region consists of CDR1, CDR2 and CDR3;
[0014] The V HThe amino acid sequence of CDR1 is shown in SEQ ID No. 1;
[0015] The V H The amino acid sequence of CDR2 is shown in SEQ ID No. 2;
[0016] The V H The amino acid sequence of CDR3 is shown in SEQ ID No. 3;
[0017] The V L The amino acid sequence of CDR1 is shown in SEQ ID No. 4;
[0018] The V L The amino acid sequence of CDR2 is shown in SEQ ID No. 5;
[0019] The V L The amino acid sequence of CDR3 is shown in SEQ ID No. 6.
[0020] In one embodiment of the present invention, the V H and V L The framework regions were all derived from mouse.
[0021] In one embodiment of the present invention, the V H The amino acid sequence is shown in SEQ ID No. 7 in the sequence listing;
[0022] The V L The amino acid sequence is shown as SEQ ID No. 8 in the sequence listing.
[0023] In one embodiment of the present invention, the monoclonal antibody is any one of the following:
[0024] (a) From the above-mentioned V H and the above-mentioned V L The single-chain antibody obtained by ligation;
[0025] (b) a fusion antibody comprising the single-chain antibody described in (a);
[0026] (c) containing the above-mentioned V H and the above-mentioned V L Fab;
[0027] (d) containing the above-mentioned V H and the above-mentioned V L of complete antibodies.
[0028] The present invention also provides a biological material related to the above-mentioned monoclonal antibody or a functional fragment thereof, wherein the biological material is any one of (A1) to (A12):
[0029] (A1) a nucleic acid molecule encoding the monoclonal antibody or a functional fragment thereof;
[0030] (A2) an expression cassette containing the nucleic acid molecule described in (A1);
[0031] (A3) a recombinant vector containing the nucleic acid molecule described in (A1);
[0032] (A4) a recombinant vector containing the expression cassette described in (A2);
[0033] (A5) a recombinant microorganism containing the nucleic acid molecule described in (A1);
[0034] (A6) a recombinant microorganism containing the expression cassette described in (A2);
[0035] (A7) a recombinant microorganism containing the vector described in (A3);
[0036] (A8) a recombinant microorganism containing the vector described in (A4);
[0037] (A9) a transgenic animal cell line containing the nucleic acid molecule described in (A1);
[0038] (A10) a transgenic animal cell line containing the expression cassette of the expression vector described in (A2);
[0039] (A11) a transgenic animal cell line containing the vector described in (A3);
[0040] (A12) A transgenic animal cell line containing the vector described in (A4).
[0041] In one embodiment of the present invention, the nucleic acid molecule (A1) is a gene encoding the above-mentioned monoclonal antibody or a functional fragment thereof.
[0042] In one embodiment of the present invention, the gene is a DNA molecule as described below:
[0043] The V H The coding sequence of CDR1 is shown in SEQ ID No.9;
[0044] The V H The coding sequence of CDR2 is shown in SEQ ID No.10;
[0045] The V H The coding sequence of CDR3 is shown in SEQ ID No.11;
[0046] The V L The coding sequence of CDR1 is shown in SEQ ID No.12;
[0047] The V L The coding sequence of CDR2 is shown in SEQ ID No.13;
[0048] The V L The coding sequence of CDR3 is shown in SEQ ID No.14.
[0049] The present invention also provides the use of the above-mentioned monoclonal antibody or its functional fragment or the above-mentioned biological material in preparing a reagent for detecting porcine pseudorabies virus gE protein.
[0050] The embodiments of the present invention have the following advantages:
[0051] Experiments have shown that the present invention uses the pseudorabies virus gE protein expressed by insect cells to prepare a monoclonal antibody capable of binding to the pseudorabies virus. The monoclonal antibody has a strong ability to bind to the virus, good specificity and strong stability.
[0052] The detection reagent prepared by using the anti-pseudorabies virus gE protein monoclonal antibody of the present invention has high specificity, good sensitivity and good compliance rate. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.
[0054] The structures, proportions, sizes, etc. illustrated in this specification are only used to match the contents disclosed in the specification so as to facilitate understanding and reading by persons familiar with the technology. They are not used to limit the conditions under which the present invention can be implemented, and therefore have no substantial technical significance. Any structural modification, change in proportion or adjustment of size shall still fall within the scope of the technical contents disclosed in the present invention without affecting the effects and purposes that can be achieved by the present invention.
[0055] Figure 1 The purity identification diagram of the Bacv-PRV-gE recombinant protein provided in the embodiment of the present invention shows that the target protein band size is 63 KD;
[0056] Figure 2 The results provided in the embodiments of the present invention show the SDS polyacrylamide gel electrophoresis diagram of the purified anti-PRV gE protein monoclonal antibody;
[0057] Figure 3A homology analysis diagram of the nucleotide sequence of the heavy chain variable region of the anti-PRV gE protein monoclonal antibody provided in an embodiment of the present invention;
[0058] Figure 4 A homology analysis diagram of the nucleotide sequence of the light chain variable region of the anti-PRV gE protein monoclonal antibody provided in an embodiment of the present invention;
[0059] Figure 5 A homology analysis diagram of the amino acid sequence of the heavy chain variable region of the anti-PRV gE protein monoclonal antibody provided in an embodiment of the present invention;
[0060] Figure 6 This is a homology analysis diagram of the amino acid sequence of the light chain variable region of the anti-PRV gE protein monoclonal antibody provided in the embodiment of the present invention. DETAILED DESCRIPTION
[0061] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0062] The experimental methods in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are commercially available unless otherwise specified.
[0063] Example 1. Preparation of recombinant protein of pseudorabies virus gE
[0064] The method for preparing the recombinant protein of pseudorabies virus gE provided in this embodiment comprises the following steps:
[0065] 1. Construction of the recombinant shuttle vector Bacmid-PRV
[0066] The gE gene was synthesized according to the PRV-gE sequence (AF207700.1) logged in GenBank, and the gE gene was connected to the pFastBac™1 vector. At the same time, the codons were optimized to adapt to insect cell expression, and SmaⅠ and PvuⅡ restriction sites were selected. The synthesized recombinant plasmid was transformed into DH10Bac engineering bacteria to obtain a recombinant transformed strain. The recombinant transformed strain was spread on a screening medium plate (containing 50 μg / mL kanamycin, 7 μg / mL gentamicin, 10 μg / mL tetracycline, 40 μg / mL X-gal and 40μg / mL IPTG). After 48 hours, blue and white colonies appeared on the plate. The white colonies were picked and streaked on the screening medium plate. After two purifications, white colonies were obtained. The colonies were screened and cultured, and the plasmid was extracted to obtain the recombinant shuttle vector Bacmid-PRV gE plasmid vector, which was transfected into insect cells.
[0067] 2. Preparation of recombinant baculovirus
[0068] SF9 insect cells were cultured in a 27°C incubator until the cell density reached 8.0×10 5 cells / mL, 1µg of Bacmid-PRV gE plasmid was transfected into SF9 insect cells by Cellfectin®II Reagent. No contamination was observed within 24 hours after transfection, and lesions were observed after 72 hours. The first-generation recombinant baculovirus P1 was collected, and the cells and supernatant were taken for SDS-PAGE gel electrophoresis and Western blot detection to analyze and determine whether the target protein has been normally expressed. Subsequently, the P1 generation virus was used to continue to infect the supernatant of SF9 insect cells to obtain the P2 generation recombinant baculovirus, and the obtained P2 generation recombinant baculovirus was frozen at -80℃.
[0069] 3. Identification of recombinant protein purity
[0070] The purity of the purified Bacv-PRV-gE protein was detected by protein SDS-polyacrylamide gel electrophoresis. The specific steps are as follows: prepare 12% separation gel and 5% concentration gel, carefully inject the separation gel liquid into the gap of 1.5 mm glass plate to a height of 10 cm, cap with pure water, polymerize at room temperature for 20 min, discard the pure water, add the concentration gel liquid on top to a height of 1 cm, carefully insert the comb to avoid bubbles in the gel, and polymerize at room temperature for 10 min. Add a quarter volume of 5× loading buffer to 20 μL sample and mix well, and heat at 100°C for 10 min. 25 μL of sample was loaded into each well at 80V for 20 min, and the program was changed to 120V after 50 min. After bromophenol blue reached the bottom of the separation gel, the colloid was taken out and placed in Coomassie brilliant blue dye solution. The colloid was oscillated and stained for 2 h. The colloid was washed with water, and the excess dye solution was removed and replaced with decolorizing solution. The decolorizing solution was replaced every 30 min until the protein band was clear. The protein band was analyzed and identified as the Bacv-PRV-gE protein band. Figure 1 As shown, the purity of the Bacv-PRV-gE recombinant protein was identified. It can be seen that the target band size is 63 KD, the band is clear, and there are no mixed bands, which meets the purification standards.
[0071] Example 2: Preparation of monoclonal antibodies against pseudorabies virus gE protein
[0072] This embodiment provides a method for preparing a monoclonal antibody against the gE protein of pseudorabies virus of porcine, which comprises the following steps:
[0073] 1. Animal immunization
[0074] The porcine pseudorabies virus gE recombinant protein expressed by the recombinant baculovirus and purified in Example 1 was used as an immunogen, mixed with an equal amount of Freund's immune adjuvant, fully emulsified, and immunized BALB / C mice at a dose of 50 μg / mouse for the first immunization. Subsequently, the immunization dose of 50 μg / mouse was mixed with an equal volume of Freund's incomplete adjuvant and emulsified for subcutaneous multiple-point immunization.
[0075] The interval between each immunization was 2 to 3 weeks. Seven days after the third immunization, blood was collected from the tip of the mouse tail to detect the immune titer. After the mouse tail blood was collected, it was placed at 4°C for 30 min to precipitate the serum. The serum was taken and diluted in multiples with PBS. At the same time, blank mouse serum was used as a control and the treatment method was the same as that of mouse serum. The OD of the experimental group and the control group was 450nm The maximum serum dilution factor when the ratio is greater than 2.1 is the mouse serum titer. Mice with high titers were selected and boosted by intraperitoneal injection of 50 μg of pseudorabies virus gE recombinant protein antigen and an emulsion of an equal volume of PBS with incomplete Freund's adjuvant (200 μL). The mice were killed 3 days later and cell fusion was performed.
[0076] 2. Cell fusion
[0077] Blood was collected from the eyeballs of mice that had completed booster immunization, and serum was separated as a positive control. After the mice were killed by cervical dislocation, they were immersed in 75% ethanol for 10 min, and then fixed on the dissection table in the clean bench. Use sterilized tweezers to lift the abdominal skin, use sterile scissors to cut a small piece of skin from the lower abdomen upward, separate the skin and peritoneum, carefully open other internal organs, separate the spleen, gently remove it, and place it in a culture dish containing 20 mL of incomplete DMEM culture medium. Use a syringe filled with 20 mL of incomplete DMEM culture medium to pierce the top of the spleen, penetrate the spleen, gently push the syringe, blow out the spleen cells in the culture dish, repeat several times until the spleen no longer changes color, and filter the spleen cells with a filter.
[0078] SP2 / 0 and spleen cells were counted, spleen cells and SP2 / 0 were mixed at a cell ratio of 8:1, inverted to mix, and centrifuged at 1000 rpm for 4 min; in a 37°C water bath, the precipitated cells were tapped to make them evenly distributed at the bottom of the tube, and allowed to stand for 1 min. Within 1 min, 1 mL of PEG1450 was added to the centrifuge tube and allowed to stand for 1 min. Within 30 s, 1 mL of incomplete DMEM culture medium preheated at 37°C was added along the tube wall to terminate the cell fusion reaction; the tip of the pipette was inserted under the liquid surface, 1 mL of incomplete DMEM was added within 1 min, and this step was repeated until 20 mL of incomplete DMEM culture medium was added; 30 mL of incomplete DMEM culture medium was slowly added, and centrifuged at 800 rpm for 4 min, the supernatant was discarded, and 50 mL of incomplete DMEM culture medium was added, and centrifuged at 800 rpm for 4 min. The supernatant was discarded, and HAT culture medium was added. The cells were gently blown up and added to a 96-well cell culture plate (200 μL / well), mark it; perform indirect ELISA identification 7 days later.
[0079] 3. Screening of positive hybridoma cells for anti-PRV gE protein monoclonal antibodies
[0080] The hybridoma cell supernatant was taken and the positive hybridoma cells were screened by indirect ELISA. 450nm For wells with high values and only single cell clumps, discard the culture medium and add 200 μL HT culture medium. Pipette and count the cells. Take about 200 cells to spread half a 96-well plate. Passage the remaining cells to a 48-well plate for further expansion and cryopreservation. After 7 days, the monoclonal cells were identified by ELISA and subcloned again using the above method. After 3 subclones, select the cells with OD 450nm Single cell clusters with higher OD values can be cloned again according to the above method. 450nm The OD values of the wells with high values are those without cell aggregates. 450nmIf the value is not higher than that of the negative control, it is considered to be a monoclonal cell line that can secrete anti-PRV gE protein monoclonal antibodies.
[0081] 4. Purification and preparation of anti-PRV gE protein monoclonal antibody
[0082] The cell lines secreting PRV gE protein antibodies obtained by screening were injected into the peritoneal cavity of mice for cultivation, and ascites was extracted from the peritoneal cavity of mice for purification. The specific operation steps are as follows:
[0083] 500 μL of Freund's incomplete adjuvant was injected intraperitoneally into mice. After 24 h, approximately 1×10 7 The hybridoma cells were injected into the peritoneal cavity of mice, and the ascites was collected 7 days later. The antibody was purified using a commercial antibody purification kit, and the specific operation was as follows: centrifuge the ascites at 10,000 rpm for 10 min, collect the supernatant, and take 20 μL to make a sample; add 60 μL 1M Tris-HCl (pH=9.0) to the centrifuge tube; filter the Binding buffer and Elution buffer with a 0.45 μm filter for later use; dilute the ascites twice with Binding buffer; fill a syringe with 10 mL Binding buffer and connect it to the purification column, remove the bubbles and slowly push the piston to remove the storage solution; draw 10 mL Binding buffer at a flow rate of 1 mL / min to balance the column; draw the diluted ascites with a syringe at a flow rate of 0.2 mL / min to allow the antibody to bind to the column; fill 10 mL Binding buffer to wash away the unbound antibody until the outflowing liquid is colorless; draw 5 mL Elution buffer to elute the antibody bound to the column and add it dropwise to the above centrifuge tube with Tris-HCl, 8 drops / tube. 20 μL of sample was taken from each tube to prepare the sample; the antibody was analyzed after SDS-PAGE protein electrophoresis, Coomassie brilliant blue staining and decolorization, the purity of the monoclonal antibody was identified, and the monoclonal antibody against PRV gE protein was obtained by PBS dialysis. Figure 2 As shown, the results showed that the concentration of the purified anti-PRVgE protein monoclonal antibody was 17 mg / ml, and SDS polyacrylamide gel electrophoresis analysis showed clear immunoglobulin heavy chains and light chains without mixed bands, indicating that the antibody purity met the expected requirements.
[0084] 5. Verification of the activity of monoclonal antibodies against PRV gE protein
[0085] The anti-PRV gE protein monoclonal antibody was analyzed by SDS-PAGE, dialyzed, and the concentration was measured, and finally the activity was verified by ELISA. ELISA detection steps: coated with purified PRV-gE antibody 0.1 μg / mL, 100 μL / well; incubated with 0.1% gelatin at 37°C for 2h; washed with 250 μL / well of 0.1% PBST washing solution 3 times; diluted porcine pseudorabies virus 100 μL / well, incubated at 37°C for 1 h (the control group did not add inactivated virus, and each group was repeated three times); washed with 250 μL / well of 0.1% PBST washing solution 3 times; 100-fold diluted porcine pseudorabies positive serum and negative serum, 100 μL / well, incubated at 37°C for 30 min; washed with 250 μL / well of 0.1% PBST washing solution 3 times; pat dry and add HRP enzyme-labeled rabbit anti-swine secondary antibody (diluted 1:10000 in PBS) 100 μL / well, incubated at 37°C for 30 min; washed again 3 times, pat dry and add commercial TMB The color developing solution was 100 μL / well and the color was developed at room temperature for 10 min. Finally, 0.5 M sulfuric acid was added at 50 μL / well to terminate the reaction and the OD was measured with an enzyme-labeled instrument. 450nm The results of the anti-PRV gE protein monoclonal antibody activity test are shown in Table 1.
[0086] Table 1
[0087]
[0088] 6. Sequencing of monoclonal antibodies against PRV gE protein
[0089] Total RNA of hybridoma cells was extracted, and specific upstream and downstream universal primers for mouse heavy chain antibody gene and light chain antibody gene were designed. The primers are as follows:
[0090] Heavy chain upstream primer: TGAGGAGACGGTGACCGTGGTCCCTTGGCCCC;
[0091] Heavy chain downstream primer: AGGTSMARCTGCAGSAGTCWGG;
[0092] Light chain upstream primer 1: CCGTTTGATTTCCAGCTTGGTGCC;
[0093] Light chain upstream primer 2: CCGTTTTATTTCCAGCTTGGTCCC;
[0094] Light chain upstream primer 3: CCGTTTTATTTCCAACTTTGTCCC;
[0095] Light chain upstream primer 4: CCGTTTCAGCTCCAGCTTGGTCCC;
[0096] The light chain downstream primer was GACATTGAGCTCACCCAGTCTCCA. The cDNA of the heavy chain and light chain was amplified using an RT-PCR kit. The cDNA was connected to the pMD18-T cloning vector and sequenced to obtain the gene sequence of the anti-PRV gE protein monoclonal antibody.
[0097] V H Heavy chain variable region nucleotide gene sequence (SEQ ID No.15):
[0098] gaggtgcagctgcaggagtctgcacatgagctcgtgaagcctggggcttcagtgaagataccctgcaaggcttctggatacacattcactgactacaacatgcactgggtgaagcagagcctccgaaagagccttgagtggattggagatattcatcctaacaatggtggtactatctacaaccagaag tgcatgggcaaggccacattgactgtagacaagtcctccagcacagccgacatggagctccgcagcctgacatctgacgacactgcagtctattcctgtgcaagagaggggattcattgctacggtagttgctacgtacggtacgacttggactactgccgccaaggcaccactctcacagtctcctca.
[0099] V H The coding sequence of CDR1 is shown in SEQ ID No.9: gactacaacatgcac;
[0100] V H The coding sequence of CDR2 is shown in SEQ ID No.10:
[0101] gatattcatcctaacaatggtggtactatctacaaccagaagtgcatgggc;
[0102] V H The coding sequence of CDR3 is shown in SEQ ID No.11:
[0103] gaggggattcattgctacggtagttgctacgtacggtacgacttggactac.
[0104] V HHeavy chain variable region amino acid sequence (SEQ ID No.7):
[0105] EVQLQESAHELVKPGASVKIPCKASGYTFTDYNMHWVKQSLRKSLEWIGDIHPNNGGTIYNQKCMGKATLTVDKSSSTADMELRSLTSDDTAVYSCAREGIHCYGSCYVRYDLDYCRQGTTLTVSS.
[0106] V L Light chain variable region nucleotide gene sequence (SEQ ID No.16):
[0107] gatactgtgctgacccagagctcggcgagcctggctgtgagcctgtgccagcgcgcgaccattagctgcaaagcgagccagagcgtggatcatgatggcgatagctatatgaactggtctcagcagagaccgagccagagctc gacactgctgatttatgcggcgagcaacctggaaagcggcattcctgcgcgctttagctgcagcggcagccgcaccgattttaccctgaacattcatcctgtggaagaagaagatgcggcgacctattattgccagcagacc.
[0108] V L The coding sequence of CDR1 is shown in SEQ ID No.12:
[0109] aaagcgagccagagcgtggatcatgatggcgatagctatatgaac;
[0110] V L The coding sequence of CDR2 is shown in SEQ ID No. 13: gcggcgagcaacctggaaagc;
[0111] V L The coding sequence of CDR3 is shown in SEQ ID No.14, cagcag.
[0112] Light chain variable region amino acid sequence (SEQ ID No.8):
[0113] DTVLTQSSASLAVSLCQRATISCKASQSVDHDGDSYMNWSQQRPSQSSTLLIYAASNLESGIPARFSCSGSRTDFTLNIHPVEEEDAATYYCQQT.
[0114] 7. Antibody nucleotide homology analysis
[0115] The heavy chain and light chain variable region nucleotides of the anti-PRV gE protein monoclonal antibody were input into the NCBI database for comparison and homology analysis. The results are as follows Figure 3 and Figure 4 As shown, Figure 3 Homology analysis of the nucleotide sequence of the heavy chain variable region of the monoclonal antibody against PRV gE protein. Figure 4 The nucleotide sequence homology of the light chain variable region of the anti-PRV gE protein monoclonal antibody was analyzed. The analysis results showed that the monoclonal antibody heavy chain variable region gene sequence had the highest homology with the mouse immunoglobulin heavy chain variable region (Sequence ID: KU256551.1), with a homology of 361 / 379 and a homology percentage of 95%; the anti-PRV gE protein monoclonal antibody light chain variable region gene sequence had the highest homology with the mouse immunoglobulin light chain variable region (Sequence ID: KM393286.1), with a homology of 272 / 285 and a homology percentage of 95%.
[0116] 8. Antibody amino acid homology analysis
[0117] The amino acids of the heavy and light chain variable regions of the anti-PRV gE protein monoclonal antibody were input into the NCBI database for comparison and homology analysis. The results are as follows Figure 5 and Figure 6 As shown, Figure 5 To analyze the amino acid sequence homology of the heavy chain variable region of the monoclonal antibody against PRV gE protein. Figure 6 The amino acid sequence homology of the light chain variable region of the anti-PRV gE protein monoclonal antibody was analyzed. The analysis results showed that the amino acid sequence of the heavy chain variable region of the anti-PRV gE protein monoclonal antibody had the highest homology with the mouse immunoglobulin heavy chain variable region (Sequence ID: AML31200.1), with a homology of 110 / 126 and a homology percentage of 87%; the amino acid sequence of the light chain variable region of the anti-PRVgE protein monoclonal antibody had the highest homology with the mouse immunoglobulin light chain variable region (Sequence ID: AKH14756.1), with a homology of 85 / 95 and a homology percentage of 89%.
[0118] 9. CDR region analysis of anti-PRV gE protein monoclonal antibody
[0119] The heavy chain variable region CDR region and light chain variable region CDR region of the anti-PRV gE protein monoclonal antibody were analyzed at https: / / www.novopro.cn / tools / cdr.html to obtain the heavy chain and light chain CDR regions of the anti-PRV gE protein monoclonal antibody. The analysis results are shown in Table 2, which is the amino acid sequence of the heavy chain and light chain variable region CDR region, and Table 3 is the amino acid sequence of the light chain variable region CDR region.
[0120] Table 2
[0121]
[0122] Table 3
[0123]
[0124] Example 3: Application of anti-PRV gE protein monoclonal antibody in the preparation of enzyme-linked immunosorbent assay reagent for detecting pseudorabies virus gE antibody
[0125] 1. This embodiment provides the use of an enzyme-linked immunosorbent assay kit for detecting porcine pseudorabies virus gE antibodies prepared with PRV gE monoclonal antibodies. The detection process of the detection kit includes the following steps:
[0126] Take out the antigen-coated plate from the kit, dilute the serum to be tested twice with the sample diluent on the serum dilution plate (mix 60 μl of sample diluent and 60 μl of serum to be tested), take 100 μl of the mixture and add it to the ELISA plate, and add 2 wells of positive serum and negative serum respectively, 100 μl in each well.
[0127] Gently shake the samples in each well, cover the coated plate with a sealing film, and incubate at 37°C for 30 min.
[0128] Discard the solution in the wells and add 250 μl of working wash solution to each well, repeat 3 times. After the last wash, pat the liquid dry thoroughly.
[0129] Add 100 μl of enzyme-labeled antibody to each well, cover the coated plate with a sealing film, and incubate at 37°C for 30 min.
[0130] Discard the solution in the wells and add 250 μl of working wash solution to each well, repeat 3 times. After the last wash, pat the liquid dry thoroughly.
[0131] Add 100 μl of substrate solution to each well, cover the coated plate with a sealing film, and incubate at room temperature for 10 min.
[0132] Add 50 μl of stop solution to each well to terminate the reaction.
[0133] The absorbance (OD) of the samples and controls at 450 nm was measured.450nm ).
[0134] Interpretation standard: IN = (negative control OD 450nm - Sample OD 450nm ) / negative control OD 450nm IN ≥ 0.45 is positive; IN < 0.45 is negative.
[0135] 2. Specificity of the ELISA test reagent for detecting antibodies against pseudorabies virus gE
[0136] The pseudorabies virus ELISA gE antibody detection kit is used to detect standard antibody positive sera for pseudorabies, classical swine fever, foot-and-mouth disease (type O), porcine circovirus type 2, porcine reproductive and respiratory syndrome, and pseudorabies antibody negative sera.
[0137] The test results are shown in Table 4. The specific serum test results show that, except for the PRV standard antibody positive serum whose IN value is significantly greater than 0.45, the other serum IN values are less than 0.45, which meets the judgment standard of negative serum, indicating that the detection kit of the present invention has good specificity.
[0138] Table 4
[0139]
[0140] 3. Sensitivity test of enzyme-linked immunosorbent assay for pseudorabies virus gE antibody
[0141] The PRV standard antibody positive serum was diluted 2, 4, 8, 16, 32, and 64 times respectively, and the detection kit of the present invention and the purchased porcine pseudorabies virus ELISA gE antibody detection kit were used for simultaneous detection. The results are shown in Table 5 for the sensitivity serum detection results of the detection kit of the present invention. The detection kit of the present invention can detect the PRV standard antibody positive serum diluted 32 times, and the purchased kit can also detect the PRV standard antibody positive serum diluted 16 times, indicating that the porcine pseudorabies virus ELISA gE antibody detection kit established by the present invention has good sensitivity.
[0142] Table 5
[0143]
[0144] 4. The compliance rate of the enzyme-linked immunosorbent assay for the detection of pseudorabies virus gE antibodies of the present invention
[0145] The detection kit of the present invention and the purchased porcine pseudorabies virus ELISA gE antibody detection kit were used to simultaneously detect 30 serum samples. The results were compared as shown in Table 6. The overall sample detection conformity rate of the detection kit of the present invention and the purchased kit was 97%, indicating that the detection kit of the present invention has a good correspondence with the control kit.
[0146] Table 6
[0147]
[0148] Table 7
[0149]
[0150] The present invention provides a porcine pseudorabies virus gE antibody, the antibody sequence of which is different from the known published gE antibody sequence, the monoclonal antibody has a strong affinity for the virus, and has high sensitivity and strong specificity. The detection kit prepared using the antibody has the advantages of high specificity, good sensitivity and high compliance rate.
[0151] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
Claims
1. A monoclonal antibody against the gE protein of pseudorabies virus, characterized in that: The monoclonal antibody contains a H The heavy chain variable region and the name V L The light chain variable region of The V of the monoclonal antibody H The amino acid sequence is shown in SEQ ID No. 7; The V of the monoclonal antibody L The amino acid sequence is shown in SEQ ID No. 8; The V H and V L Both are composed of complementary determining regions and framework regions, wherein the complementary determining regions are composed of CDR1, CDR2 and CDR3; The V of the monoclonal antibody H The amino acid sequence of CDR1 is shown in SEQ ID No. 1; The V of the monoclonal antibody H The amino acid sequence of CDR2 is shown in SEQ ID No. 2; The V of the monoclonal antibody H The amino acid sequence of CDR3 is shown in SEQ ID No. 3; The V of the monoclonal antibody L The amino acid sequence of CDR1 is shown in SEQ ID No. 4; The V of the monoclonal antibody L The amino acid sequence of CDR2 is shown in SEQ ID No. 5; The V of the monoclonal antibody L The amino acid sequence of CDR3 is shown in SEQ ID No.
6.
2. The monoclonal antibody against pseudorabies virus gE protein according to claim 1, characterized in that: The V H and V L The framework regions were all derived from mouse.
3. The monoclonal antibody against pseudorabies virus gE protein according to claim 1 or 2, characterized in that: The monoclonal antibody is any of the following: (a) V according to claim 1 or 2 H and V according to claim 1 or 2 L The single-chain antibody obtained by ligation; (b) containing V according to claim 1 or 2 H and V according to claim 1 or 2 L Fab; (c) containing V according to claim 1 or 2 H and V according to claim 1 or 2 L of complete antibodies.
4. A biological material related to the monoclonal antibody according to any one of claims 1 to 3, wherein the biological material is any one of (A1) to (A12): (A1) a nucleic acid molecule encoding the monoclonal antibody according to any one of claims 1 to 3; (A2) an expression cassette containing the nucleic acid molecule described in (A1); (A3) a recombinant vector containing the nucleic acid molecule described in (A1); (A4) a recombinant vector containing the expression cassette described in (A2); (A5) a recombinant microorganism containing the nucleic acid molecule described in (A1); (A6) a recombinant microorganism containing the expression cassette described in (A2); (A7) a recombinant microorganism containing the vector described in (A3); (A8) a recombinant microorganism containing the vector described in (A4); (A9) a transgenic animal cell line containing the nucleic acid molecule described in (A1); (A10) a transgenic animal cell line containing the expression cassette described in (A2); (A11) a transgenic animal cell line containing the vector described in (A3); (A12) A transgenic animal cell line containing the vector described in (A4).
5. The biomaterial according to claim 4, characterized in that (A1) The nucleic acid molecule is a gene encoding the monoclonal antibody according to any one of claims 1 to 3.
6. The biomaterial according to claim 5, characterized in that The gene is a DNA molecule as described below: The V H The coding sequences of CDR1, CDR2 and CDR3 are shown in SEQ ID No.9, SEQ ID No.10 and SEQ ID No.11 respectively; L The coding sequences of CDR1, CDR2 and CDR3 are shown in SEQ ID No.12, SEQ ID No.13 and SEQ ID No.14, respectively.
7. Use of the monoclonal antibody according to any one of claims 1 to 3 or the biological material according to any one of claims 4 to 6 in the preparation of a reagent for detecting porcine pseudorabies virus gE protein.
